News

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...
A federal court ruled in Mylan's favor, finding no infringement of Novo's patent tied to Wegovy, rejecting direct, ...
Novo Nordisk sees 65% obesity drug sales growth, forecasts $8.14–$9.59B FY25 free cash flow. Click here to read an analysis ...
Novo Nordisk NVO generates most of its revenues from the sales of its blockbuster GLP-1 injections, Ozempic for type II ...
After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...
Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...
The partnership helps Novo capture patients who have been using compounded versions of the medicine, while allowing ...
Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
GoodRx reports on identifying real Wegovy pens, which come in five colors and lack dose selectors. Counterfeits pose health ...
In Novo Nordisk A/S’s home country of Denmark, the popularity of weight-loss drugs is fueling economic growth, but local retailers are now warning they will take a hit as food consumption declines.
Wegovy® is indicated for chronic weight management in adults and adolescents (12+) with obesity or overweight and at least one related health condition. The once-weekly injectable supports weight loss ...